Vidarbha News

The Bronchiectasis market outlook is expected to change positively in the upcoming years because of increased global healthcare spending, improved awareness, and the proliferation of major players

 Breaking News
  • No posts were found

The Bronchiectasis market outlook is expected to change positively in the upcoming years because of increased global healthcare spending, improved awareness, and the proliferation of major players

August 09
20:05 2021
The Bronchiectasis market outlook is expected to change positively in the upcoming years because of increased global healthcare spending, improved awareness, and the proliferation of major players
Bronchiectasis Market
The launch of therapies such as Brensocatib/INS 1007 and others are anticipated to provide a major push to the growth of the Bronchiectasis market size in the forecast period 2021-30 in the 7MM.

DelveInsight’s Bronchiectasis market report provides a comprehensive understanding of Bronchiectasis, historical and forecasted epidemiology, and Bronchiectasis market trends in the 7MM (the US, EU5 (Germany, Spain, Italy, France, and the UK), and Japan).

Some of the Important Findings from the Bronchiectasis Market Report

  • According to the CHEST Foundation, over 110,000 Americans have Bronchiectasis and it affects women more than men.

  • Insmed Incorporated, Zambon, Novartis, and others are among the major companies that are involved in developing novel therapies for Bronchiectasis treatment.

  • Brensocatib/INS 1007 (Insmed Incorporated) is a novel oral reversible dipeptidyl peptidase 1 inhibitor (DPP1). In June 2020, the US FDA designated it as a breakthrough therapy for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB). The drug is currently being evaluated in a Phase III study in Non-Cystic Fibrosis Bronchiectasis patients.

  • Colistimethate Sodium (Zambon) is an antibiotic used to treat Pseudomonas aeruginosa infections, and the I-Neb AAD system is an inhalation system that delivers nebulized medications into the lungs. Colistimethate Sodium Powder is being tested in two Phase-III pivotal trials for the prevention of pulmonary exacerbations in adult patients with Non-Cystic Fibrosis Bronchiectasis colonized with Pseudomonas aeruginosa.

  • QBW251 (Novartis) is a drug that opens the cystic fibrosis transmembrane conductance regulator (CFTR) channel, allowing chloride to be transported. Currently, the drug is in Phase II of development for Bronchiectasis treatment.

Request for the sample to get a complete overview of the disease @ Types of Bronchiectasis

The Bronchiectasis market report also covers current treatment practices, emerging drugs, Bronchiectasis market share of individual therapies, and current and forecasted Bronchiectasis market Size from 2018 to 2030, segmented by seven major markets.

Bronchiectasis: Overview

Bronchiectasis is a chronic condition in which the bronchial walls thicken due to inflammation and infection. Exacerbations are periodic flare-ups of breathing difficulties in people with Bronchiectasis. Bronchiectasis symptoms can develop slowly over months or years and worsen over time. Coughing and mucus (sputum) production on a daily basis are the two primary Bronchiectasis symptoms. Bronchiectasis is of two types: Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis (NCFB).

Bronchiectasis Epidemiology Segmentation

The Bronchiectasis report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Bronchiectasis Total Prevalent Cases

  • Bronchiectasis Gender-Specific Cases

  • Bronchiectasis Etiology-Specific Cases 

  • Bronchiectasis Severity-Specific Cases 

  • Bronchiectasis Age-Specific Cases 

  • Bronchiectasis Total Diagnosed and Treated Cases 

Bronchiectasis Treatment Landscape

Despite the fact that no medications have been approved by regulatory agencies for Bronchiectasis treatment, a variety of drugs and strategies have shown benefits in improving both quality of life and clinical outcomes. The current Bronchiectasis treatment options include:

  • Antibiotics (Macrolides)

  • Bronchodilators 

  • Anti-inflammatory therapy

  • Mucus Thinning Medication

Bronchiectasis Market

The launch of therapies such as Brensocatib/INS 1007, Colistimethate Sodium, QBW251,and others by key pharmaceutical companies such as Insmed Incorporated, Zambon, Novartis, and several others is anticipated to provide a major push to the growth of the Bronchiectasis market size in the forecast period 2021-30 in the 7MM. 

Bronchiectasis Pipeline Therapies and Key Companies 

  • Brensocatib: Insmed Incorporated

  • Colistimethate Sodium: Zambon

  • QBW251: Novartis

For more details on the emerging drugs and companies, visit New Treatments for Bronchiectasis

Table of Contents

1.

Key Insights

2.

Bronchiectasis: Market Overview at a Glance

3.

Executive Summary

4.

Organizations

5.

Patient Journey

6.

Disease Overview: Bronchiectasis 

7.

Bronchiectasis Epidemiology and Patient Population

8.

Bronchiectasis: Country-wise Epidemiology

9.

Bronchiectasis Unmet Needs

10.

Bronchiectasis Emerging Therapies

11.

Bronchiectasis: Market Outlook

12.

Bronchiectasis Market Drivers

13.

Bronchiectasis Market Barriers

14.

Bronchiectasis Market Access and Reimbursement

15.

SWOT Analysis

16.

Case studies

17.

KOL Views

18.

Appendix

19.

Disclaimer

20.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Non-Cystic Fibrosis Bronchiectasis Market

Get comprehensive historical and forecast analysis of Non-Cystic Fibrosis Bronchiectasis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Aradigm Corporation, Zambon, Novartis Pharmaceuticals, Insmed Incorporated, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/